Pfizer
RUXIENCE
Manufacturer:
Pfizer
Name:
RUXIENCE
HCPCS Code Descriptor:
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Category:
Q Code
HCPCS:
Q5119
NDC(s):
00069-0238-01, 00069-0249-01
Primary Type:
Oncology Biosimilar
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
RUXIENCE is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5119 is aligned to the drug RUXIENCE.
Ruxience targets the CD20 protein in red blood cells and is used to treat certain types of cancer and autoimmune disorders. Ruxience is manufactured by Pfizer and is biosimilar to the medication Rituxan (J9311). Ruxience was aligned to the HCPCS code Q5119 in July 2020. Patient assistance programs for this medication can be found through Pfizer enCompass.